PROTAGONIST THERAPEUTICS, INC. (PTGX) Return on equity 2017–2025
PROTAGONIST THERAPEUTICS, INC. (PTGX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-21.2%FY2025 · since FY2017: -30.6% → -21.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -21.2% | -61.9 pp |
| FY2024 | 40.8% | +64.2 pp |
| FY2023 | -23.5% | +35.6 pp |
| FY2022 | -59.1% | -17.2 pp |
| FY2021 | -41.8% | -18.2 pp |
| FY2020 | -23.7% | +72.9 pp |
| FY2019 | -96.5% | -61.9 pp |
| FY2018 | -34.6% | -4.0 pp |
| FY2017 | -30.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice